**Appendix Table D4. Study design characteristics**

| **Author, Year**  **PMID**  **Country**  **Study name** | **Study design** | **Multicenter (yes/no)** | **Recruitment method** | **Sampling population** | **Enrollment period** | **Mean or median (state which follow up duration)** | **Setting** | **A Priori power analysis performed? (if yes, was accrual 80% of target or higher)** | **Funding** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Collet, 2009  19108880  France  AFIJI (Appraisal of risk Factors in young Ischemic patients Justifying aggressive Intervention) registry | Prospective observational, registry based study | YES | Convenience sample of patients from a registry of AMI in patients <45 yr, on clopidogrel for ≥1 mo, with available genotyping information | Young patients with AMI (STE MI or NSTE MI) | The registry covers the period from April, 1996 to April, 2008; patients entered before 1999 (year when clopidogrel became available in the study population) were excluded | Median clopidogrel exposure = 1.07 yr (IQR = 0.28, 3.0)  Maximum FU = 8 yr  Mean followup = 2.7 yr for CYP2C19 \*2 carriers; 2.9 yr for CYP2C19 non-carriers  Mean followup = 2.84 yr | Patients were survivors of AMI enrolled in a multicenter registry; followup was on an outpatient basis | Not performed | Non-industry |
| Fontana, 2008  17681590  Switzerland | Prospective observational study | YES | Consecutive patients who received PCI with stenting in a single center | Patients undergoing PCI with stent placement | NR | Measurements after ≥15 d under clopidogrel (median FU = 19 d; IQR = 15-47) | Inpatient for PCI; outpatient for followup after discharge | Power calculations performed; enrolled 81 patients out of a planned sample size of 100 | Non-industry only |
| Giusti, 2007  18004210  Italy  NR | Observational study, prospective (measurements 24 h after PCI) | NO | Consecutive patients | Patients with ACS, undergoing primary PCI | NR | 24 h post PCI | Inpatient | no (posthoc only) | Non-industry only |
| Giusti, 2009  19268736  Italy  RECLOSE study  (Low Responsiveness to Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent Thrombosis) | Prospective observational study of patients enrolled in the RECLOSE study in a single center | NO  (single center recruitment for this study) | Consecutive patients consenting to genetic study identified from the RECLOSE study population | Patients with ACS or CAD undergoing PCI with stenting | July 2005 to August 2006  [recruitment period of the RECLOSE study; information from pmid = 17572245] | 6 months  (unclear what metric; from the KM curves implied maximum FU) | In hospital (PCI) | Not performed | Non-industry only |
| Gladding, 2009  19926050  New Zealand  NR | Prospective “open label dose escalation study with molecular randomization” | No | NR | Patients who had undergone PCI >2 weeks previously and were on clopidogrel | NR | Total 7 days | Inpatient, with outpatient followup after the inpatient procedure | Yes (“~90%”) | NR  (except “genotyping” was “supplied” by AutoGenomics, which is the affiliation of one of the authors) |
| Jinnai, 2009  19531897  Japan  Partly industry funded | Prospective | Unclear | Convenience sample | Patients scheduled for PCI | NR | Maximum 28 days; results reported only up to 48 hours | In-patient; patients undergoing elective PCI | Not performed | Partly industry funded |
| Mega, 2009  19106084  Multinational  Genetics substudy of TRITON-TIMI 38 [Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction] | Prospective cohort study (genetics substudy of RCT, only one of the randomized arms included) | YES | Sub study of RCT | Patients with ACS (STE MI, NSTE MI ,UA) planned for PCI | 2004-2007 | 15 months | Inpatient | Not performed | Industry funding |
| Shuldiner, 2009  19706858  USA  Sinai Hospital of Baltimore Study | Retrospective, based on medical records (based on followup procedures) | NO | Convenience | CAD patients undergoing non-emergent PCI | January 2004–May 2007 | 12 months post-PCI | In-patient in a single catheterization laboratory (non-emergent PCI) | Not performed | Non-industry only |
| Sibbing, 2009  19193675  Germany  NR | Prospective observational study | NO | Convenience sample; patients participating in several randomized clinical trials of abciximab | CAD patients undergoing PCI | May 2000–December 2005 | Complete followup to 30 days | Inpatient for PCI, outpatient followup for the duration of the study followup. Patients with cardiac symptoms were seen in the outpatient clinic for further investigation | Not performed [power analysis was performed post hoc, based on the observed effect size] | Non-industry only  (several authors with COI) |
| Sibbing, 2010  20083681  Germany  Part of a prospective study of the Multiplate analyzer | Observational study, prospective | NO | Consecutive patients recruited from a study of the Multiplate analyzer | Patients with CAD with planned DES implantation; patients were eligible regardless of clinical presentation (stable angina, UA, STE MI, or NSTE MI). | February 2007–April 2008 | 30 d ±7 days (all outcomes adjudicated at that time-point by phone interview with outpatient clinic visits for those reporting cardiac symptoms) | Inpatient for elective PCI (patients were hospitalized for ≥2 days); patients were the interviewed by phone (outpatient) and those reporting symptoms were examined in the outpatient clinic (for clinical, EKG, and laboratory checkup) | Not performed | Partly industry supported (material provided by manufacturer of the Multiplate analyzer, which was used here as a reference standard) |
| Varenhorst, 2009  19429918  Sweden  NR | Prospective observational study  (genetics sub study of RCT comparing antiplatelet regimens) | Yes  (2 centers in Sweden) | Sub study of RCT | Patients with CAD (~98% had received PCI before inclusion in the parent trial) | April 2006 to December 2006  [for the parent study] | Maximum followup 29 d±3 d (last measurements obtained) | Outpatients who had regular visits for reactivity measurements | Not performed (for the genetic sub-study) | Industry funded |
| Frere, 2008  18394438  France  NR | Prospective | NO | Consecutive patients | NSTE ACS patients undergoing angiography | 2004–2006 | ≥12 h after loading | Inpatient | NO | NR |
| Frere, 2009  19496924  France  Part of larger observational study | Retrospective | NO | Convenience | NSTE ACS patients undergoing angiography | 2004–2006 | NR  (measurements appear to have been obtained after the clopidogrel loading dose) | In-patient, single cardiology department | Not performed | NR  (authors’ stated that there was “no conflict of interest”) |
| Bonello-Palot, 2009  19932784  France  NR | Prospective observational study | YES | Convenience sample | Patients undergoing percutaneous coronary intervention (PCI) for ACS; Patients with acute coronary syndromes (ACS) | Aug 2007–Mar 2008 | NR (patients were followed up from admission till the PCI was performed) | Inpatient | Not performed | Partly Industry |
| Harmsze 2010  19934793  Netherlands  NR | Prospective observational cohort | NO | Consecutive patients | Patients undergoing percutaneous coronary intervention (PCI) for ACS | NR | NR | Inpatient | Not performed | Partly Industry |
| Trenk 2008  18482659  Germany  EXCELSIOR (Impact of Extent of Clopidogrel-Induced Platelet Inhibition During Elective Stent Implantation  on Clinical Event Rate) | Prospective observational study | NO | Substudy of the EXCELSIOR prospective study | CAD patients undergoing elective PCI with stent implantation | NR | 30 day follow up for all patients, and 12 month follow up for 795 patients (99.1%) | followup after intervention | no (power analysis for the parent study) | Non-industry only |
| Tantry, 2010  21079055  Multicountry- North America and Europe  Genetic substudy of ONSET/ OFFSET and RESPOND | RESPOND and ONSET/OFFSET were randomized, double-blind, double-dummy, multicenter studies.  RESPOND was crossover; ONSET/OFFSET was parallel-group (prospective) | YES | Sub study of RCT | Adults with stable coronary artery disease receiving aspirin who consented to genotyping | RESPOND, May 19, 2008, to March 25, 2009  ONSET/OFFSET, October 2007 toMarch 2009 | 2-6 weeks | Outpatient | For both RESPOND and ONSET/OFFSET,  YES  [YES]  Not done for genetic substudy (they took whoever consented) | All industry |
| Wallentin, 2010  20801498  Multinational (43 countries in North America, South America, Europe, Asia, Australia)  PLATO | Prospective observational study | YES | Sub study of RCT | ACS patients with <80% undergoing PCI | October 2006 through July 2008 | Median, 277 days | Inpatient | NO (not prospectively powered and had to be based on the maximum number of patients consenting to provide a blood sample for genetic analysis) | All Industry |
| Hochholzer, 2010  20510210  Germany  EXCELSIOR | Prospective cohort | No | Unclear | Patients  undergoing  PCI with stenting | NR | 30 days to 6 months | inpatient | Not performed | NR |
| Jeong 2010  20650435  Korea  ACCEL-DOUBLE | Cohort | No | Sub study of RCT | Patients with CAD undergoing PCI | Jan 2008-June 2009 | ≥1 mo | inpatient | it was estimated that a total of 95 patients (57 carriers and 38 noncarriers of the *CYP2C19* variant allele) would be required to provide a power of 90% to detect a statistically significant difference with a 2-sided alpha-level of 0.05. | NR |
| Barker, 2010  20965456  USA  NR | Prospective cohort | No | Selected CAD patients; unclear methods | CAD patients had clopidogrel for >7 days or high OTR | NR | Mean 8 days | Unclear | Yes, 90% | Non-industry |
| Bonello, 2010  20708365  France  NR | Prospective cohort | Yes | Selected sample of Patients with PCI | Patients with PCI | Jan 2009-Jan 2010 | NR | Inpatient | Not performed | NR |
| Gurbel 2011  21392617  USA  NR | Cohort | No | Unclear | Patients had established coronary artery disease (CAD) and were on aspirin (81-325 mg/d) therapy for a minimum of 2 weeks were studied (N = 261). | NR | NR | Outpatient | Yes. Given the frequency of the \*2 allele in the population, to determine a 20% absolute difference in the prevalence of HPR between these 2 groups, a sample size of 105 patients was required with an a = .05 and power of 80%. | Non-industry |
| Hwang 2011  21075428  South Korea  NR | Cohort | No | Consecutive patients | CAD patients undergoing elective PCI with stent implantation | Jan 2008-March 2009 | NR | Inpatients from Department of Cardiology of the Gyeongsang National University Hospital | Not performed | Non-industry |
| Kang, 2010  20724801  Korea  NR | Cohort | No | Consecutive | CAD patients with elective stent implantation | July 2008-June 2009 | NR | Hospital | Not performed | Non-industry |
| Liu 2010  21163112  China  NR | Cohort | No | Consecutive | Patients were admitted for elective coronary intervention with symptomatic stable CAD. | Oct 2006-Sep 2007 | 12 months minimum | Hospital | Not performed | NR |
| Maeda, 2010  21178986  Japan  NR | Cohort | No | NR | CAD | NR | >4 weeks | Unclear | Not performed | NR |
| Malek, 2010  20924183  Poland  NR | Cohort | No | Consecutive | AMI with and without ST-elevation, PCI with stenting was attempted. | 2005-2005 | 4 years | Hospital | Not performed | Non-industry |
| Simon 2011  21262992  France  FAST-MI | Prospective observational study (registry-based) | Yes | Consecutive | AMI patients undergoing PCI (<80%) | 2005-2006 | 1 year | Inpatient ( from ICU) | Not performed | Partly industry |
| Simon 2011  19106083  France  FAST-MI | Prospective observational study (registry-based) | Yes | Consecutive | AMI patients undergoing PCI (<80%) | 2005-2006 | 1 year | Inpatient ( from ICU) | Not performed | Partly industry |
| Yamamoto 2011  21168310  Japan  NR | cohort | No | Consecutive | CAD undergoing angiography (and PCI when needed); PCI(for those assessed for clinical outcomes) | NR | 340 days | Inpatient | Not performed | NR |
| Park 2011  21345843  Korea  CILON-T | Randomized trial | yes | Sub study of RCT | CAD patients undergoing PCI with stenting | 2006-2009 | 6 months | Inpatient | Yes 18 non-carriers and 11 carriers of CYP2C19-LOF would be needed to provide a power of 95% to detect a statistically significant difference between groups with a two-sided a-level of 0.05. | Non-industry |
| Tiroch, 2010  20826260  Germany  NR | Cohort | No | Consecutive | AMI patients with >90% of them undergoing PCI with BMS placement | 2005-2008 | 1 year | Inpatients in a Hospital | yes  80% | NR |
| Sorich, 2010  20492467  707 sites in 30 countries  Substudy of TRITON-TIMI 38 | Substudy of RCT | Yes | Selected sample | PCI | November 2004 and January 2007. | 6 to 15 months. | Hospital (inpatient) | Not performed | Industry |
| Sibbing, 2010  20492469  Germany  NR | Cohort | No | Consecutive | Stable CAD patients undergoing angiography | Aug 2007 to Sep 2008 | NR | Inpatients in a Hospital | Not performed | NR [Speaker fee from industry by first author] |
| Sawada, 2010  21099121  Japan  NR | Cohort | No | NR | PCI | Jan 2008-Jan 2010 | 243.8±88.1 days  Median 223.5 days, range 7–546 days | In patients at Kobe University Hospital | Not performed | NR |
| Pare, 2010  20979470  Multinational  CURE | Prospective cohort study | Yes | Sub-study of RCT | Patients with ACS-NSTE | 1998–2000 | 3.6 years | Inpatient | NO | Industry |
| Pare, 2010  20979470  Multinational  ACTIVE-A | Prospective cohort study | Yes | Sub-study of RCT | Patients with AFIB | 2000–2006 | 3–12 months | Outpatient | NO | Industry |
| Mega, 2010  20801494  707 sites in 30 countries  TRITON-TIMI 38 | Prospective cohort study | Yes | Sub study of RCT | ACS | November 2004 and January 2007. | 6–15 months. | Inpatient | Not performed | Industry |
| Bouman 2011  21628721  Netherlands  Genetic substudy of the Popular study | Prospective, observational, single-center cohort study | NO | Consecutive sampling (but then patients without DNA samples were excluded) | Patients with CAD taking clopidogrel undergoing elective coronary stent implantation and who were genotyped | December 2005 and December 2007 | Total 1 year | Inpatient/outpatient followup after intervention | Not performed | NR but authors received speakers fee from industry.  (NB Popular study received platelet-testing equipment from industry) |
| Campo 2011  21679849  Italy  NR | Prospective cohort | No | Consecutive | Patients undergoing PCI for ischemic heart disease who had a baseline and 1 month PRU evaluation and a baseline blood sample for genotyping | December 2008 to May 2009 | Max, 1 year | Inpatient followed by outpatient followup | Not performed | NR but authors have COIs with drug companies |
| Fernando 2011  21696537  Australia  NR | Prospective (randomized crossover study design) | NO | Unclear | Patients with ACS and stents on aspirin but not clopidogrel | NR | Duration for all patients who completed study, 14 weeks (6 weeks in each study arm with 2-wk washout in between) | Outpatient | YES  80% | Non-industry only |
| Geisler 2008  18781853  Germany  NR | Prospective pharmacogenetic trial | NO | Consecutive | Caucasian patients undergoing PCI for CAD | July 2006-March 2007 | NR | Inpatient | YES (86%) | NR except “The authors have no relevant financial involvement with any…entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes…grants…received or pending…” |
| Gladding 2008  19463375  New Zealand  PRINC (Plavix Response in Coronary Intervention) Trial | 2 by 2 factorial, randomized, placebo-controlled, double-blind study over the ﬁrst 24 h, followed by a 1-week randomized, placebo-controlled, double-blind study | NR | Sub study of RCT | Patients undergoing elective PCI | NR | 7 Days total | Inpatient, with outpatient followup after the inpatient procedure | YES  [YES (“~80%”)] | Non-industry  (except VerifyNow analyzer was provided by Sanofi Aventis) |
| Gurbel 2010  19817997  USA  NR | Prospective comparative? | NO | Unclear | Patients with stenting and stable condition who were screened for HPR | Feb. 1,-Sept. 15, 2008 | NR (max. follow-up, 7 to 10 days) | Outpatient | Not performed | All industry |
| Harmsze 2010  20833683  Netherlands  NR | Retrospective case-control | YES | Consecutive enrollment | Patients undergoing PCI with stenting | Cases: January 2004 to February 2007  Controls: December 2005 and December 2006 | Total, 1 yr from the time of PCI | Hospital/outpatient | Not performed | Partly industry |
| Kim 2011  21511217  South Korea  ACCELAMI2C19  High-dose clopidogrel | Randomized prospective | NO | Sub study of RCT | 62 AMI patients treated with emergent PCI receiving a high-MD of clopidogrel | 2007-2009 | 30 days | Inpatient | YES  [YES] 80% | Partly industry |
| Kim 2011  21511217  South Korea  ACCELAMI2C19  Cilostazol group | Randomized prospective | NO | Sub study of RCT | 64 AMI patients treated with emergent PCI receiving an adjunctive dose of cilostazol | 2007-2009 | 30 days | Inpatient | YES  [YES] 80% | Partly industry |
| Lee 2011  21786436  South Korea  NR | Retrospective | NO | Selection of patients with testing for resistance and polymorphism | Patients with cerebrovascular disease who received clopidogrel and were tested for clopidogrel resistance and CYP2C19 polymorphism | January 2009 to June 2010 | NR | Outpatient | Not performed | Non-industry only |
| Malek 2008  18577829  Poland  NR | Prospective observational | Unclear | NR | Patients with any ACS undergoing PCI and receiving clopidogrel and aspirin | NR | 12 months | Inpatient and then outpatient followup (by phone) | Not performed | Non-industry only |
| Pettersen 2011  21426546  Norway  Aspirin and Clopidogrel non-responsiveness clinical Endpoint Trial (ASCET) | Prospective observational study | NO | Consecutively included randomized clopidogrel group from ASCET (n=219) | CAD patients randomized to receive maintenance clopidogrel (<80% PCI) | October 2005 to June 2008 | NR | Outpatient | Not performed | Non-industry only |
| Sibbing 2011  21527445  Germany  NR | Prospective cohort | NO | For PCI cohort: volunteers for DNA sampling from prospective trial (1524/1608 [95%])  For early ST cohort, consecutive recruitment and DNA sample availability | CAD patients undergoing PCI with stenting (>95%) and receiving clopidogrel and aspirin and who had DNA samples | For PCI cohort (who were the control cohort also), Feb 2007–April 2008 | NR | Inpatient | Not performed [ | Non-industry only [except “material for platelet function analysis on the Multiplate device was provided free of charge from Dynabyte”] |
| Sibbing 2011  21527445  Germany  NR | Case-control | NO | Consecutive | CAD patients undergoing PCI with stenting | 1999-2008 | NR | Inpatient | Not performed | Non-industry only [except “material for platelet function analysis on the Multiplate device was provided free of charge from Dynabyte”] |
| Simon 2009  19106083  France  FAST-MI | Prospective observational | YES | Consecutive | Patients with AMI in a French registry receiving clopidogrel | October 1–December 24, 2005 | Total 1 year | Inpatient (for the subgroup undergoing PCI); outpatient followup | Not performed | Partly industry |
| Hwang 2010  20823393  Korea  ACCEL-RESISTANCE, DM, COMPLEX  (High-dose clopidogrel group) | Prospective cohort  Hwang | No | Sub study of RCT | High-risk CAD patients undergoing PCI | Jan 2008–June 2009 | 30 days | Inpatient | Not performed | Non industry |
| Hwang, 2010  20823393  Korea  ACCEL-RESISTANCE, DM, COMPLEX  (Triple antiplatelet therapy group) | Prospective cohort  Hwang | No | Sub study of RCT | High-risk CAD patients undergoing PCI | Jan 2008–June 2009 | 30 days | Inpatient | Not performed | Non industry |
| Bouman, 2011  Multinational  21170047  NR | Case-cohort study | Yes | Random (for controls); incident cases (convenience because of refusals) | Patients with CAD undergoing PCI with stenting | 2003–2007 | 18 mo | Inpatient | Yes (but not for CYP2C19 variants) | No funding information; reported that the authors had no financial conflicts of interest |
| Bouman  2011  Multinational  21170047  NR | Prospective cohort | Yes | Convenience sample | Patients undergoing PCI with stenting | 2007–2009 | 12 months | Inpatient | Yes(80%) | No funding information; reported that the authors had no financial conflicts of interest |
| Price, 2012  22624833  US  GIFT (Genotype Information and Functional Testing) Study—a prespeciﬁed genetic substudy of GRAVITAS (Gauging Responsiveness with A VerifyNow assay–Impact on Thrombosis And Safety) trial | Genetic substudy of randomized, multicenter trial (GRAVITAS) | YES (all in North America) | Subsample of GRAVITAS patients—those with samples for genotyping and who were randomized to receive clopidogrel | Adults with CAD or ACS undergoing PCI with at least 1 DES, with or without high on-treatment platelet reactivity | July 2008–April 2010 | Total 6 mo | 48 Hospital centers | YES (YES: 80%) | All industry |
| Gremmel, 2012  22154242  Austria  NR | Prospective observational | NO | NR | CAD patients undergoing stenting | Jan. 2008-Nov. 2010 | ~1 day (no followup time points) | Hospital (Medical University of Vienna, Division of Angiology) | NO (NA) | NR |
| Harmsze, 2012  22228204  Netherlands  POPular substudy | Genetic substudy of prospective POPular study but otherwise NR | YES | Consecutive (part of POPular) | CAD patients undergoing elective stenting | NR | 1 yr total | Hospital and then outpatient followup | NO (NA) | NR |
| Kreutz, 2012  22427735  US  NR | Observational | NO | NR | CAD patients receiving clopidogrel | NR | 1 day total | Hospital visit for measurements | NO (NA) | NR |
| Dai, 2012  22704413  China  NR | Prospective observational | NO | NR | Patients undergoing PCI and stenting† | July 2009-April 2011 | 1 month | Hospital for intervention, outpatient measurement of reactivity at 10 days, and telephone contact with outpatients at 1 month | NO (NA) | NR |
| Cuisset, 2011  21803320  France  NR | Prospective cohort | no | consecutive | NSTE ACS patients undergone PCI | July 2008- Jan 2010 | 1 month | inpatient | no | NR |
| Chen. 2012  22723959  Taiwan  CAPTAIN | cohort study | no | registry | CAD patients undergone PCI with stenting | Nov 1995-June 2011 | NR | inpatient | NR | non-industry |
| Gajos, 2012  22623230  Poland  OMEGA-PCI | RCT | no | consecutive | patients with stable CAD undergoing PCI | NR | 1 month | inpatients | NR | NR |
| Luo, 2011  22118006  China  NR | prospective cohort | no | consecutive | patients with stable CAD undergoing PCI | March 2006-May 2010 | 6 months | inpatients and then outpatients | NR | non-industry |
| Tello-Montoliu 2012  22116003  Spain  study one of the paper | cohort for first objective | no | selective patients undergone PCI | stable ACS patients with stent | NR | NR | outpatient clinic | NR | non-industry |
| Tello-Montoliu 2011  22116003  Spain  Second objective | cohort for second objective | no | consecutive | non-ST elevation acute coronary syndrome | NR | 6 months | inpatient | NR | non-industry |
| Harmsze, 2011  21854540  Netherlands  NR | prospective | no | consecutive | CAD for PCI | NR | 1 year | inpatient | NR | industry |
| Ono, 2011  21862109  Japan  NR | NR | No | consecutive | CAD for PCI | Oct 2008-Nov 2010 | 12 months | inpatients then follow up | NR | non-industry |
| Delaney, 2012  22190063  USA  NR | NR | NR | BioVU database | patients started clopidogrel after an MI and/or PCI with stent placement | NR-June 2011 | 2 years | Vanderbilt DNA biobank | NR | non-industry |
| Bhatt, 2012  22450429  USA  CHARISMA | subset of RCT | yes | RCT | patient on clopidogrel for high atherothrombotic risk and ischemic stabilization | NR | 800 days | NR | NR | industry |
| Fontana 2011  21692977  Switzerland  ADRIE | prospective cohort | yes | consecutive | ischemic atherothrombotic disease (CAD, ICD, PAD) | June 2006-Dec 2008 | 3 years | inpatient | NR | non-industry |
| Aleil, 2009  19624462  France  VASP-02 [genetic reanalysis thereof] | Genetic posthoc analysis of RCT (nonblinded) | YES | NR | Adults without ACS undergoing elective stenting | April 2005-Dec. 2007 | Total 1 mo | Inpatient | NO (NA) | Partly industry |
| Chen, 2012  22071359  China  NR | Prospective observational | NO | Consecutive | Adults with CAD | July 2008-Sept. 2009 | Mean 11.42 mo | Inpatient for angiography, outpatient thereafter | NO (NA) | Nonindustry |
| Kreutz, 2012  22385219  USA  NR | Prospective observational | NO | NR | Adults with stable CAD | NR | 15 days | Outpatient | NO (NA) | Nonindustry |
| Marcucci, 2012  22390861  Italy  NR | Prospective observational | NO | NR | Adults undergoing PCI and stenting for ACS | NR | 12 mo | Inpatient | NO (NA) | Nonindustry |
| Nishio, 2012  22785462  Japan  NR | Prospective observational | NO | NR | Patients undergoing PCI with DES stenting | June 2008-June 2010 | Mean 646.2 days, median 692.5 days | Inpatient | NO (NA) | NR |
| Park, 2012  22507978  Korea  ACCEL-STATIN | RCT (patients enrolled already having received clopidogrel and already ascertained as having HPR; randomization was for pravastatin or rosuvastatin) | NO | “Prospective” | Adults with HPR having had a PCI with >=6 mo of antiplatelet therapy | April 2009-Dec. 2011 | 15 day total | Inpatient | YES (YES) | Nonindustry (article says “partly funded” by nonindustry and does not mention industry) |
| Teixeira, 2012  22377481  Portugal  NR | Prospective observational | NO | NR | Patients <75 yr admitted for ACS and survived | March [or April—one stated in one place and one another place]-Oct 2009 | Median 136.0 days after discharge | Inpatient | NO (NA) | NR |
| Parri, 2012  22727972  Italy  NR | RCT (with randomization only to pantoprazole or ranitidine) | NO | NR | Patients with STEMI and undergoing PCI | July 2009-Feb 2010 | 30 days total | Inpatient | YES (YES) | NR |
| Yamane, 2012  22472213  Japan  NR | cohort study | no | NR | patients with prior coronary stent implantation who had received dural anti-platelet therapy | Sep 2009 and May 2011 | ≥ 4 weeks | inpatient | yes (<80%) | non-industry |
| Hsu, 2011  21144850  Taiwan  NR | open label RCT | no | consecutive | atherosclerotic disease such as ischemic heart disease or stroke | Aug 2008 to Jan 2010 | 6 months | inpatient | yes (90%) | non-industry |
| Kim, 2012  22007612  Korea  ACCEL-TRIPLE | prospective cohort | no | NR | PCI treated patients | Jan 2008–June 2009 | 1 months | inpatients | yes (90%) | non-industry |
| Siller-Matula, 2012  22260716 Austria PEGASUS-PCI | prospective cohort | no | consecutive | patients undergoing PCI | March 2007–Nov 2009 | 12 months | inpatient and then followup | yes, 80% | Austrian National Bank |
| Bonello, 2012  22285300 France NR | prospective | yes | NR | PCI for non-ST elevation Acute Coronary Syndrome (NSTE ACS) | January 2010–September 2011 | 6-12 hours after clopidogrel loading dose | Inpatient | No | Non-industry (Research grant from the Assistance Publique - Hopitaux de Marseille) |
| Simon, 2011  21918510 France FAST-MI | Prospective observational study (registry-based) | Yes | Consecutive | All AMI patients (and a subset of AMI patients undergoing PCI) | November 2005 | 1 year | Inpatient (from ICU) and then outpatient followup | No | Partly industry |
| Collet, 2011 21511218 France CLOVIS-2 | RCT-Crossover trial | NR | Selected sample (from a registry) | Patients who had survived an MI before age 45 | NR | 6 hours (between baseline and measurement of platelet reactivity) | Inpatient | Yes; >80% of target | Non-industry only |
| Jaitner, 2012  22298798 Germany NR | Cases from a registry and controls from a prospective cohort | No | Cases from a registry with a DES thrombosis & event free patients from a cohort of subjects undergoing PCI for CAD | CAD patients undergoing PCI with stenting | For PCI cohort (who were the control cohort also), Feb 2007–April 2008  Cases: 1999–2008 | NR | Inpatient | No | Non-industry only |
| Mega, 2011  22088980 USA ELEVATE-TIMI 56 | RCT | Yes | Consecutive | CAD patients on clopidogrel | October 2010–September 2011 | 2 weeks | Outpatient | Yes; >80% of target | Industry |
| Hochholzer, 2011  21884870  NR  EXCELSIOR | Prospective cohort | NR | NR | CAD patients undergoing PCI with stenting | NR | 24 hours | Inpatient | No | NR |
| Kassimis, 2012  21831410  Greece  NR | Prospective | No | Consecutive | CAD patients undergoing PCI with stenting | NR | 24 hours | Inpatient | No | NR |
| Namazi, 2012  22265638  Iran  NR | Prospective | No | NR | CAD patients undergoing PCI with stenting | September 2007–October 2008 | 30 days | Inpatient and then outpatient | No | Non-industry only |
| Rideg, 2011  21806387  Hungary  DOSER | Substudy of RCT | No | consecutive | CAD stable angina patients undergoing PCI with stenting | February 2008–September 2009 | 1 year | Inpatient and then outpatient | No | Non-industry only |
| Jeong, 2011  22045970  Korea  NR | Prospective | No | selected sample | AMI patients who underwent angiography | September 2007–August 2009 | 1 year | Inpatient and then outpatient | yes (accrual >80%) | Non-industry only |
| Chan,2012  22462746  Singapore  NR | Prospective | No | selected sample | CAD patients undergoing PCI or angiography | NR | 7 days | Inpatient; followup after intervention | No | Industry and Non-industry |
| Goodman, 2012  22261200  Multi-country  PLATO | Clopidogrel arm of an RCT | Yes | consecutive | ACS patients undergoing PCI | NR | 1 year | Inpatient and then outpatient | No | Industry only |
| Park, 2012  22735685  Korea  CROSS-VERIFY | Prospective | No | consecutive | CAD patients undergoing PCI | June 2006–June 2010 | 12 months | Inpatient and then outpatient | No | Non-industry only |
| Kreutz, 2012  22459907  USA  NR | Prospective | No | Selected sample | CAD patients undergoing PCI | NR | 16-24 hours | Inpatient | No | Non-industry only |
| Yan, 2011  21778720  China  NR | Prospective | No | Consecutive | ACS patients undergoing PCI | NR | 24 months (NR in text, seen in Fig 1) | Inpatient and then outpatient | No | Non-industry only |
| Jeong, 2012  22837373  Korea  ACCEL-DM | prospective cohort | no | selected sample | type 2 diabetes undergoing PCI | NR | 30 days | inpatient then followup | yes (90%) | NR |
| Cayla, 2011  22028352  France  ONASSIST | case-control study | Yes | Consecutive | Patients undergoing PCI with stenting | January 2007–May 2010 | NR | Inpatient | Yes | Industry and on-industry grants |
| Hulot, 2011  21972404  France  AFIJI | prospective cohort | Yes | Convenience sample | AMI before age 45 | NR | 2.6 yr (median clopidogrel exposure time) | NR | no | Non-industry only |
| Hulot, 2011  21972404  France  CLOVIS-2 | prospective cohort | Unclear | Substudy of RCT | AMI before age 45 | NR–April 2008 | 6 hours | inpatient | No | Non-industry only |
| Roberts, 2012  22464343  Canada  RAPID GENE | RCT | no | NR | NSTE-ACS or chronic CAD undergoing PCI with stenting | August 2010–July 2011 | 30 days | inpatient | yes | Industry and on-industry grants |

**Abbreviations:** ACS = acute coronary syndrome; AMI = acute MI; BMS=Bare metal stents; BP = blood pressure; CABG = coronary artery bypass grafting; CAD = coronary artery disease; DES=Drug eluting stent; HTN = hypertension, IV=Intravenous; LD=Loading dose; MD=Maintenance dose; MI = myocardial infarction; NR=Not reported; NSTE = non-ST-elevation;NSTEMI = non-ST-elevation MI; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; RCT=randomized controlled trials; STEMI = ST-elevation MI; TIA = transient ischemic attack; UFH=Unfractionated Heparin; ICD, ischemic cerebrovascular disease.  
†Patients were selected for “blood stasis syndrome” (a diagnosis in traditional Chinese medicine) but also for having undergone PCI with stent placement. Because patients were only eligible if they had undergone PCI and were enrolled after PCI, the study was included.